Dextroamphetamine Adipate

CHEMBL1200782 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
281.4 g/mol
LogP
Phase
4

Central nervous system stimulation by dextroamphetamine follows from increased dopaminergic and noradrenergic signalling, and the adipate is one salt form in which the active moiety is supplied. Attention deficit hyperactivity disorder and narcolepsy are the two established indications, conditions in which enhanced catecholamine transmission improves attentional control or wakefulness respectively. The salt form influences pharmaceutical properties rather than the receptor pharmacology, which remains that of the parent amphetamine enantiomer. Its recorded formula is C15H23NO4 with a molecular weight near 281.4 g/mol. The agent is approved as a small molecule and has completed the final phase of clinical development within the stimulant class.

An adipate salt form of dextroamphetamine, a stimulant that affects the central nervous system by increasing levels of dopamine and norepinephrine. It is used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy.

الوزن الجزيئي

281,3500 g/mol

TPSA

101,00 Ų

المجالات العلاجية

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H](N)Cc1ccccc1.O=C(O)CCCCC(=O)O

InChI

InChI=1S/C9H13N.C6H10O4/c1-8(10)7-9-5-3-2-4-6-9;7-5(8)3-1-2-4-6(9)10/h2-6,8H,7,10H2,1H3;1-4H2,(H,7,8)(H,9,10)/t8-;/m0./s1

Molecular Formula

C15H23NO4

HBD / HBA

3 / 5

الروابط القابلة للدوران

7

الذرات الثقيلة

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An adipate salt form of dextroamphetamine, a stimulant that affects the central nervous system by increasing levels of dopamine and norepinephrine. It is used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy.

Yes, Dextroamphetamine Adipate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200782. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 49800024. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.